CLDXCelldex Therapeutics, Inc.

Celldex Therapeutics, Inc. (NASDAQ: CLDX) | Price: $35.60 | Today's Change: -6.04%

---

What Happened

Celldex Therapeutics filed an 8-K with the SEC on September 22, 2026, under Items 8.01 and 9.01, disclosing financial data that includes results for Q2 FY2026. The filing reveals a net loss of $53.8 million and an operating loss of $126.6 million for the second quarter of FY2026, against modest contract revenues of approximately $1.42 million for the same period. The magnitude of the operating loss — nearly 89 times the quarter's reported revenue — underscores the company's stage as a clinical-stage biopharmaceutical firm with substantial ongoing R&D and operating expenditures.

---

Why It Matters

For investors, the key takeaway is that Celldex continues to operate at a significant cash burn rate. With Q2 FY2026 operating losses of $126.6 million and contract revenues of only $1.42 million, the company remains heavily dependent on its existing cash reserves and any future capital raises to fund operations and advance its pipeline. The basic and diluted EPS of -$1.66 for the quarter further illustrates the per-share impact of the ongoing loss. Shares are trading down 6.04% on the day, suggesting the market is reacting meaningfully to the disclosed figures. Investors should note that no revenue figure from the current fiscal year remotely offsets operating expenses, a pattern consistent with a pre-commercial clinical-stage company — though a legacy FY2018 revenue figure of $1.534 million is also present in the filing's XBRL data, likely tied to historical contract or grant revenue reported in the filing's exhibits.

---

Analysis

The scale of the operating loss — $126.6 million in a single quarter — is significant even by the standards of well-funded clinical-stage biotechs, and warrants close attention to how management characterizes the drivers of that spend. In the absence of product revenues, every dollar of operational outlay is effectively a bet on pipeline success. The gap between operating loss ($126.6M) and net loss ($53.8M) is also notable: the roughly $72.8 million difference implies meaningful non-operating income (potentially from interest on a large cash and investment portfolio), which is an important buffer for the company's runway, but does not change the underlying cash consumption profile of the operating business.

Key things to watch going forward:

• Pipeline milestone disclosures: Given the burn rate, any Phase 2/3 readout or FDA interaction will be a critical catalyst in either direction.
• Cash and liquidity update: The filing does not provide a balance sheet cash figure in the structured facts provided — investors will want to scrutinize the company's cash position to assess how many quarters of runway remain at this burn rate.
• Capital markets activity: A loss of this scale in a single quarter elevates the probability of a follow-on equity offering, which would be dilutive to existing shareholders.
• Item 8.01 specifics: This item covers "other events" not covered by other 8-K items — the precise nature of the disclosure under this item should be reviewed in the full filing on EDGAR, as it may contain pipeline, partnership, or corporate updates beyond the financial figures.

The stock's sharp -6.04% move today reflects investor sensitivity to these numbers. Given the clinical-stage nature of the business, the share price remains fundamentally driven by pipeline news rather than earnings fundamentals.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Celldex Therapeutics' SEC filing made available via EDGAR. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. No rating or price target is assigned. Readers should conduct their own due diligence and consult a qualified financial advisor before making any investment decision. Past performance is not indicative of future results.

Source

Filed with the SEC on 2026-09-22. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/744218/000110465926109465/tm2625892d1_8k.htm